

# Health Care Portfolio

SERIES 10

## UNIT INVESTMENT TRUSTS

### Investment Objective and Principal Investment Strategy


The Health Care Portfolio, Series 10 ("Trust") seeks to maximize total return through capital appreciation with a secondary objective of current income. The Trust consists of 37 stocks of companies that are classified as being in the Health Care Sector by the Global Industry Classification Standard ("GICS"), or are believed by the Sponsor to have a significant level of revenues directly derived from health care related products and services. The Sponsor selects stocks for the portfolio that it believes have the potential to achieve the Trust's investment objective.

### Long-Term Strategy

This UIT is part of a long-term strategy. Please consider your ability to invest in successive portfolios, if available, at the applicable sales charge. Call your financial professional today or visit claymore.com to learn more.

### PORTFOLIO ALLOCATION

Weightings and breakdown are as of the date of deposit and are subject to change.



Country Weightings	
United States	83.42%
Great Britain	4.31%
Denmark	4.27%
Switzerland	4.02%
Israel	3.98%
<b>TOTAL</b>	<b>100.00%</b>
Industry Weightings	
Pharmaceuticals	38.13%
Health Care Providers & Services	18.22%
Health Care Equipment & Supplies	15.56%
Biotechnology	13.91%
Life Sciences Tools & Services	10.16%
Food & Staples Retailing	4.02%
<b>TOTAL</b>	<b>100.00%</b>

### Security Selection

The Sponsor selects U.S.-traded stocks that it believes are core holdings of a well-diversified health care portfolio. To select the portfolio, the Sponsor follows a very disciplined process that includes both quantitative and qualitative analysis. The Sponsor begins with the stocks of companies that are classified as being in the Health Care Sector by the GICS, or are believed by the Sponsor to have a significant level of revenues directly derived from health care related products and services, and are either components of the Russell 3000 Index ("R3K") or have market capitalizations larger than the smallest company within the R3K. The Sponsor then reduces the size of this universe to approximately 250 stocks by performing quantitative screening, which may be primarily based on, but not limited to, the following factors:

- Valuation
- Growth
- Profitability

The Sponsor then reduces the 250 securities to 37 stocks by performing qualitative analysis, which may be primarily based on, but not limited to, the following factors:

- Balance Sheet
- Industry Leadership
- Valuation
- Growth
- Profitability

### The Aging of America

The Sponsor believes that the health care sector should benefit from the aging American population. Government studies demonstrate that the growth in the population of Americans over the age of 65 will increase over time and spending on health care typically increases with age. Consider the following statistics:

"The Baby Boomers (those born between 1946 and 1964) will start turning 65 in 2011, and the number of older people will increase dramatically during the 2010–2030 period. The older population in 2030 is projected to be twice as large as in 2000, growing from 35 million to 71.5 million and representing nearly 20 percent of the total U.S. population."<sup>1</sup>

"The U.S. Census Bureau projects that the population age 85 and over could grow from 5.3 million in 2006 to nearly 21 million by 2050. Some researchers predict that death rates at older ages will decline more rapidly than is reflected in the U.S. Census Bureau's projections, which could lead to faster growth of this population."<sup>1</sup>

**Past performance does not guarantee future results. There is no guarantee that these trends and projections will continue or come to fruition and they are subject to change.**

<sup>1</sup> Older Americans 2008: Key Indicators of Well-Being, Federal Interagency Forum on Aging-Related Statistics, March 27, 2008.

### INDEX DEFINITIONS

**The Russell 3000<sup>®</sup> Index** measures the performance of the 3,000 largest U.S. companies based on total market capitalization, which represents approximately 98% of the investable U.S. equity market. It is not possible to invest directly in the Russell 3000<sup>®</sup> Index. The Trust will not try to replicate the performance of the Russell 3000<sup>®</sup> Index and will not necessarily invest any substantial portion of its assets in securities in the Indices. There is no guarantee that the perceived intrinsic value of a security will be realized.

**RISK CONSIDERATIONS** As with all investments, you may lose some or all of your investment in the Trust. No assurance can be given that the Trust's investment objective will be achieved. The Trust also might not perform as well as you expect. This can happen for reasons such as these: **Securities prices can be volatile.** The value of your investment may fall over time. Market value fluctuates in response to various factors. These can include stock market movements, purchases or sales of securities by the Trust, government policies, litigation, and changes in interest rates, inflation, the financial condition of the securities' issuer or even perceptions of the issuer. Units of the Trust are not deposits of any bank and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency. **Due to the current state of the economy, the value of the securities held by the Trust may be subject to steep declines or increased volatility due to changes in performance or perception of the issuers.** In the last year, economic activity has declined across all sectors of the economy, and the United States is experiencing increased unemployment. The current economic crisis has affected the global economy with European and Asian markets also suffering historic losses. Extraordinary steps have been taken by the governments of several leading economic countries to combat the economic crisis; however, the impact of these measures is not yet known and cannot be predicted. **Share prices or dividend rates on the securities in the Trust may decline during the life of the Trust.** There is no guarantee that the issuers of the securities will declare dividends in the future and, if declared, whether they will remain at current levels or increase over time. **The Trust includes securities issued by companies in the health care sector.** General risks of companies in the health care sector include extensive competition, generic drug sales or the loss of patent protection,

RISK CONSIDERATIONS CONTINUED ON NEXT PAGE

## PORTFOLIO HOLDINGS

Holdings and weightings are as of the date of deposit and are subject to change.

Symbol	Company Name	Symbol	Company Name
<b>BIOTECHNOLOGY (13.91%)</b>			
AMGN	Amgen, Inc.	MCK	McKesson Corporation
CELG	Celgene Corporation	PSYS	Psychiatric Solutions, Inc.
GILD	Gilead Sciences, Inc.	DGX	Quest Diagnostics, Inc.
MYGN	Myriad Genetics, Inc.	UHS	Universal Health Services, Inc.
<b>FOOD &amp; STAPLES RETAILING (4.02%)</b>			
CVS	CVS Caremark Corporation	<b>LIFE SCIENCES TOOLS &amp; SERVICES (10.16%)</b>	
<b>HEALTH CARE EQUIPMENT &amp; SUPPLIES (15.56%)</b>			
BAX	Baxter International, Inc.	BIO	Bio-Rad Laboratories, Inc.
BEC	Beckman Coulter, Inc.	CVD	Covance, Inc.
BDX	Becton, Dickinson & Company	MIL	Millipore Corporation
BCR	C.R. Bard, Inc.	PPDI	Pharmaceutical Product Development, Inc.
CMN	Cantel Medical Corporation	TECH	Techne Corporation
CYBX	Cyberonics, Inc.	TMO	Thermo Fisher Scientific, Inc.
VIVO	Meridian Bioscience, Inc.	<b>PHARMACEUTICALS (38.13%)</b>	
THOR	Thoratec Corporation	ABT	Abbott Laboratories
VAR	Varian Medical Systems, Inc.	AGN	Allergan, Inc.
<b>HEALTH CARE PROVIDERS &amp; SERVICES (18.22%)</b>			
ABC	AmerisourceBergen Corporation	AZN	AstraZeneca PLC
ESRX	Express Scripts, Inc.	BMJ	Bristol-Myers Squibb Company
HMSY	HMS Holdings Corporation	JNJ	Johnson & Johnson
LH	Laboratory Corporation of America Holdings	MRK	Merck & Company, Inc.
		NVS	Novartis AG
		NVO	Novo Nordisk A/S
		TEVA	Teva Pharmaceutical Industries Limited

**RISK CONSIDERATIONS (CONTINUED)** product liability litigation and increased government regulation. **The Trust includes securities issued by small-capitalization and mid-capitalization companies.** These securities customarily involve more investment risk than large-capitalization or more seasoned securities. Small-capitalization and mid-capitalization companies may have limited product lines, markets or financial resources and may be more vulnerable to adverse general market or economic developments. **The Trust invests in American Depositary Receipts ("ADRs").** The Trust's investment in ADRs presents additional risk. ADRs are issued by a bank or trust company to evidence ownership of underlying securities issued by foreign corporations. Securities of foreign issuers present risks beyond those of domestic securities. More specifically, foreign risk is the risk that foreign securities will be more volatile than U.S. securities due to such factors as adverse economic, currency, political, social or regulatory developments in a country, including government seizure of assets, excessive taxation, limitations on the use or transfer of assets, the lack of liquidity or regulatory controls with respect to certain industries or differing legal and/or accounting standards. **Inflation may lead to a decrease in the value of assets or income from investments. The Sponsor does not actively manage the portfolio.** The Trust will generally hold, and may continue to buy, the same securities even though a security's outlook, market value or yield may have changed. **Please see the Trust prospectus for more complete risk information.**

UITs are fixed and not actively managed. An investment in this fixed portfolio should be made with an understanding of the risks involved with owning various types of investments. Industry predictions may not materialize and securities selected for the Trust may not participate in overall industry growth, if any. There is no guarantee that the portfolio will achieve its investment objective. Units, when redeemed, may be worth more or less than their original purchase price.

This UIT is part of a long-term strategy, and investors should consider their ability to invest in successive portfolios, if available, at the applicable sales charge. There are tax consequences associated with an investment from one series to the next. Investors should consult their tax advisor to determine tax consequences associated with an investment from one portfolio to the next. Units of the portfolio may be well suited for purchase by Individual Retirement Accounts or other qualified retirement plans. Consult an attorney or tax advisor regarding tax consequences associated with the purchase of units. Claymore Securities, Inc. does not offer tax advice.

## PORTFOLIO SUMMARY

Inception Date	October 28, 2009
Termination Date	January 25, 2012
Initial Offer Price	\$10.00
Minimum Investment	\$250.00
Number of Issues	37
Historical Annual Dividend Distribution	\$0.1216
Distributions*	25th day of each month commencing on November 25, 2009, if any

\* The amount of distributions of the Trust may be lower or greater than the above-stated amount due to certain factors that may include, but are not limited to, a change in the dividends paid by issuers, a change in Trust expenses or the sale or maturity of securities in the portfolio. Fees and expenses of the Trust may vary as a result of a variety of factors including the Trust's size, redemption activity, brokerage and other transaction costs and extraordinary expenses.

## TICKETING INFORMATION

CUSIP (cash payment)	18387G349
CUSIP (reinvestment accounts)	18387G356
CUSIP (fee-cash)	18387G364
CUSIP (fee-reinvest)	18387G372
Ticker	CHCRJX

## SALES CHARGES

Sales Charge ("S/C") is based on a \$10 per unit offering price.

	Amount Per Unit	Max Per Unit %
Up-front S/C	\$0.100	1.00%
Year One Deferred S/C	\$0.245	2.45%
Creation and Development ("C&D") Fee	\$0.050	0.50%
Total S/C	\$0.395	3.95%

The deferred sales charge ("DSC") will be deducted in monthly installments on the last business day commencing July 2010 and ending September 2010. If units are redeemed prior to the DSC period, the entire DSC will be collected.

For unit prices other than \$10, percentages of initial sales charge, C&D fees, and deferred sales charges will vary. Early redemption of units will still cause payment of the deferred sales charge.

## VOLUME DISCOUNT BREAKPOINTS

Purchase Amount	Sales Charge Reductions (as a % of the Public Offering Price)
Less than \$50,000	0.00%
\$50,000 - \$99,999	0.25%
\$100,000 - \$249,999	0.50%
\$250,000 - \$499,999	0.75%
\$500,000 - \$999,999	1.00%
\$1,000,000 or more	1.50%

## NOT FDIC-INSURED • NOT BANK GUARANTEED • MAY LOSE VALUE



Claymore Securities, Inc.  
2455 Corporate West Drive  
Lisle, IL 60532  
800.345.7999  
www.claymore.com

Member FINRA/SIPC  
10/09  
UITFC-DHS-010

Investors should consider the investment objectives and policies, risk considerations, charges and ongoing expenses of the UIT carefully before investing. The prospectus contains this and other information relevant to an investment in the Trust. Please read the accompanying prospectus carefully before you invest or send money. If a free prospectus did not accompany this literature, please contact your securities representative or Claymore Securities, Inc.